RT Journal Article
SR Electronic
T1 Deleterious Variants Contribute Minimal Excess Risk in Large-Scale Testing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.21.24315653
DO 10.1101/2024.10.21.24315653
A1 Huang, Yen-Tsung
A1 Lai, En-Yu
A1 Su, Jia-Ying
A1 Lu, Hsueh-Ju
A1 Chen, Yen-Lin
A1 Wu, Jer-Yuarn
A1 Wei, Chun-yu
A1 Li, Ling-Hui
A1 Fann, Cathy S.-J.
A1 Yang, Hsin-Chou
A1 Chen, Chien-Hsiun
A1 Chen, Hung-Hsin
A1 Liu, Yi-Min
A1 Tsai, Ming-Fang
A1 Yeh, Erh-Chan
A1 Cheng, Chih-Kuang
A1 Wang, Yen-Po
A1 Chi, Nai-Fang
A1 Lee, I-Cheng
A1 Chen, Harn-Shen
A1 Hsieh, Yun-Cheng
A1 Liao, Yi-Chu
A1 Hsu, Shao-Jung
A1 Ou, Shuo-Ming
A1 Lai, Kuan-Lin
A1 Lin, Chung-Chi
A1 Chen, Yi-Jen
A1 Chang, Chia-Ming
A1 Wang, Peng-Hui
A1 Luo, Yung-Hung
A1 Chang, Yun-Ting
A1 Chen, Chih-Chiang
A1 Hsieh, Yu-Cheng
A1 Chen, Yi-Ming
A1 Hsiao, Tzu-Hung
A1 Lin, Ching-Heng
A1 Chen, Yen-Ju
A1 Chen, I-Chieh
A1 Mao, Chien-Lin
A1 Chang, Shu-Jung
A1 Chang, Yen-Lin
A1 Liao, Yi-Ju
A1 Lai, Chih-Hung
A1 Lee, Wei-Ju
A1 Tung, Hsin
A1 Yen, Ting-Ting
A1 Yen, Hsin-Chien
A1 Chang, Shy-Shin
A1 Chang, Yu-Sheng
A1 Lee, Ting-I
A1 Yeh, Shauh-Der
A1 Wu, Mei-Yi
A1 Wu, Ming-Shun
A1 Tsai, Lung Wen
A1 Zheng, Cai-mei
A1 Chien, Yu-Mei
A1 Lin, Tsung-Hsien
A1 Chen, Yen-Hsu
A1 Lan, Cheng-Che E.
A1 Yen, Jeng-Hsien
A1 Liang, Wen-Chen
A1 Chan, Te-Fu
A1 Chiou, Shyh-Shin
A1 Chuang, Shih-Chang
A1 Hwang, Shang-Jyh
A1 Lin, Yi-Jung
A1 Huang, Yu-Chuang
A1 Li, Wan-Ru
A1 Chen, Tsai-Chuan
A1 Huang, Wei-Ting
A1 Chen, Kuan-Chih
A1 Lim, Shin-Yee
A1 Shen, Yi-Shiuan
A1 Huang, Chia-Chia
A1 Chen, Chien-Hung
A1 Tian, Ya-Chung
A1 Chen, Chia-Ling
A1 Fang, Yao-Fan
A1 Fang, Ji-Tseng
A1 Yen, Yi-Hao
A1 Wu, Wei-Chi
A1 Huang, Wen-Shih
A1 Sun, Chi-Chin
A1 Chen, Mei-Jyh
A1 Lin, Ching-Hung
A1 Yang, Tsung-Hua
A1 Lee, Pei-Lin
A1 Wang, Ming-Yang
A1 Tsai, Tsen-Fang
A1 Su, Tung-Hung
A1 Liou, Jyh-Ming
A1 Yang, Shun-Fa
A1 Hsieh, Chia-Chuan
A1 Sung, Chih-Chien
A1 Kuo, Feng-Chih
A1 Lin, Shih-Hua
A1 Hueng, Dueng-Yuan
A1 Lin, Chien-Jung
A1 Shen, Hueng-Yuan
A1 Hsieh, Chang-Hsun
A1 Lin, Shinn-Zong
A1 Wang, Tso-Fu
A1 Ho, Tsung-Jung
A1 Shueng, Pei-Wei
A1 Hsieh, Chen-Hsi
A1 Jeng, Kuo-Shyang
A1 Ma, Gwo-Chin
A1 Chang, Ting-Yu
A1 Chiang, Han-Sun
A1 Lin, Yi-Tien
A1 Kao, Kuo-Jang
A1 Hung, Chen-Fang
A1 Fang, I-Mo
A1 Chen, Po-Yueh
A1 Tsui, Kochung
A1 Kwok, Pui-Yan
A1 Yao, Wei-Jen
A1 Chen, Shiou-Sheng
A1 Chen, Ming
A1 Huang, Chih-Yang
A1 Wang, Da-Wei
A1 Chen, Chun-houh
YR 2024
UL http://medrxiv.org/content/early/2024/10/22/2024.10.21.24315653.abstract
AB DNA sequencing of patients with rare disorders has been highly successful in identifying "causal variants" for numerous conditions. However, there are many reports of healthy individuals who harbor these deleterious variants, leading to the concept of incomplete penetrance and doubt about the utility of genetic testing in clinical practice and population screening. As the deleterious variants are rare, the penetrance of these variants in the population is largely unknown. We analyzed the genetic and clinical data from 486,956 participants of the Taiwan Precision Medicine Initiative (TPMI) to determine the risk difference between those with and without deleterious variants. In all, we analyzed 292 disease-relevant variants and their clinical outcomes to assess their association. We found that only 15 variants show a risk difference exceeding 5% between those with or without the variants. In essence, 87.3% of deleterious variants exhibit minimal risk differences, suggesting a limited impact on the individual and population levels. Our analysis revealed increasing trends with age in six cardiovascular and degenerative diseases and bell-shaped trends in two cancers. Additionally, we identified three clinical outcomes exhibiting a dose-response relationship with the number of deleterious variants. Our findings show that large-scale testing of deleterious variants found in the literature is not warranted, except for those exhibiting large disease risk differences.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the following agencies (grant numbers): Academia Sinica (40-05-GMM, AS-GC-110-MD02, 236e-110020) and National Development Fund, Executive Yuan (NSTC 111-3114-Y-001-001).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Boards of 17 institutes: 1. Academia Sinica (AS-IRB01-18079), 2. Taipei Veterans General Hospital (2020-08-014A), 3. National Taiwan University Hospital (201912110RINC), 4. Tri-Service General Hospital (2-108-05-038), 5. Chang Gung Memorial Hospital (201901731A3), 6. Taipei Medical University Healthcare System (N202001037), 7. Chung Shan Medical University Hospital (CS19035), 8. Taichung Veterans General Hospital (SF19153A), 9. Changhua Christian Hospital (190713), 10. Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUHIRB-SV(II)-20190059), 11. Hualien Tzu Chi Hospital (IRB108-123-A), 12. Far Eastern Memorial Hospital (110073-F), 13. Ditmanson Medical Foundation Chia-Yi Christian Hospital (IRB2021128), 14. Taipei City Hospital (TCHIRB-10912016), 15. Koo Foundation Sun Yat-Sen Cancer Center (20190823A), 16. Cathay General Hospital (CGH-P110041), 17. Fu Jen Catholic University Hospital (FJUH109001). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe genotyping and electronic medical record (EMR) data analyzed in this study are from the Taiwan Precision Medicine Initiative (TPMI) with proper approval from the TPMI Data Access Committee. In compliance with the confidentiality laws governing genetic and health data in Taiwan, the de-identified TPMI data are kept in a secure server at the Academia Sinica and not released to the public. Researchers requesting access to the individual genotyping and EMR data can do so on a collaborative basis. Instructions on requesting access to the data can be found on the TPMI official website (https://tpmi.ibms.sinica.edu.tw/www/en/).https://tpmi.ibms.sinica.edu.tw/www/en/